Dong‐wan Kim

Dong‐wan Kim's AcademicInfluence.com Rankings

Dong‐wan Kim

Philosophy

#6849

World Rank

#9958

Historical Rank

Logic

#3949

World Rank

#5183

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dong‐wan Kim's Degrees

PhD Biomedical Sciences Stanford University

Why Is Dong‐wan Kim Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dong‐wan Kim's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2016) (4871)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (2014) (2577)
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. (2015) (1690)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (2012) (1608)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer (2017) (1553)
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. (2014) (1463)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. (2012) (1194)
Ceritinib in ALK-rearranged non-small-cell lung cancer. (2014) (875)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. (2016) (849)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. (2005) (783)
Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (2004) (682)
Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer (2018) (552)
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. (2016) (551)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity (2016) (487)
Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients1 (2004) (453)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. (2017) (438)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. (2017) (433)
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. (2011) (415)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. (2017) (384)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. (2016) (373)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. (2017) (368)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. (2020) (327)
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. (2017) (277)
Elevated TGF-b1 Secretion and Downmodulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients (2004) (261)
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation (2006) (255)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. (2018) (248)
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis (2011) (209)
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. (2016) (204)
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. (2015) (196)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration (2016) (195)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. (2018) (191)
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor (2015) (186)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. (2018) (177)
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. (2018) (174)
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. (2005) (169)
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). (2012) (168)
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study (2021) (168)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial (2020) (165)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study (2019) (162)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer (2005) (159)
Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer (2011) (155)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (2016) (153)
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer (2007) (150)
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer (2013) (144)
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. (2014) (143)
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma (2013) (143)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status (2015) (141)
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. (2019) (139)
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) (2017) (139)
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). (2014) (139)
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. (2014) (137)
Palliative chemotherapy for pulmonary pleomorphic carcinoma. (2007) (136)
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report (2019) (134)
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) (2016) (131)
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. (2020) (130)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. (2009) (129)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody (2018) (120)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. (2021) (118)
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. (2012) (118)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer (2013) (118)
Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (2012) (114)
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. (2014) (112)
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma (2016) (109)
Aggressiveness of cancer-care near the end-of-life in Korea. (2008) (107)
Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors (2016) (105)
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies (2016) (103)
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) (2014) (103)
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer (2015) (102)
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3 (2016) (101)
Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. (2016) (100)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. (2020) (99)
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. (2015) (99)
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. (2018) (98)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014 (2018) (98)
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. (2016) (96)
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer (2013) (91)
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. (2008) (90)
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. (2012) (89)
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). (2019) (87)
Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study. (2017) (87)
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. (2007) (84)
The role of PET/CT in detection of gastric cancer recurrence (2009) (82)
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. (2017) (82)
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. (2003) (82)
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer (2017) (78)
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases (2016) (77)
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker (2008) (77)
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. (2013) (75)
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy (2007) (74)
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment (2011) (74)
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma (2004) (73)
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (2014) (73)
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). (2014) (72)
CPR or DNR? End-of-life decision in Korean cancer patients: a single center’s experience (2006) (71)
Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. (2019) (71)
Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. (2013) (71)
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors (2011) (69)
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer (2014) (68)
Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). (2019) (67)
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer (2017) (65)
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. (2019) (65)
Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm (2013) (64)
Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC. (2019) (64)
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. (2012) (63)
Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial. (2021) (63)
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. (2021) (62)
Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. (2013) (61)
Doxorubicin‐based chemotherapy for diffuse large B‐cell lymphoma in elderly patients (2003) (60)
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). (2015) (60)
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. (2013) (59)
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer (2007) (59)
The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. (2010) (58)
Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer (2014) (57)
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. (2019) (56)
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). (2020) (55)
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). (2018) (55)
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). (2016) (52)
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma (2006) (52)
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study (2008) (52)
Observer variability in RECIST-based tumour burden measurements: a meta-analysis. (2016) (52)
Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). (2012) (52)
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). (2020) (51)
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2017) (51)
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). (2016) (51)
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. (2013) (51)
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer (2012) (51)
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer (2010) (51)
Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer (2017) (51)
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors (2019) (50)
Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer (2013) (49)
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study. (2014) (49)
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer (2021) (48)
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. (2019) (48)
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity (2018) (47)
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. (2004) (46)
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. (2019) (46)
TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3β pathway and activation of caspases (2010) (46)
First‐line therapy with doxycycline in ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors (2010) (46)
Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute (2015) (45)
Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) (2012) (45)
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy (2009) (45)
Health‐Related Quality of Life in KEYNOTE‐010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC (2019) (45)
Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. (2016) (44)
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (2015) (44)
BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D. (2016) (44)
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor (2018) (43)
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. (2017) (43)
Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study (2012) (43)
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. (2021) (42)
Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). (2016) (42)
MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. (2015) (42)
High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy (2006) (42)
Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy (2010) (41)
Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. (2012) (41)
First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. (2012) (41)
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma (2018) (41)
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer (2020) (40)
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer (2017) (39)
First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. (2012) (39)
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis (2015) (39)
[Breast cancer in the early stage]. (2012) (39)
Scientific Advances in Thoracic Oncology 2016. (2017) (39)
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. (2015) (39)
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. (2014) (39)
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy (2011) (38)
Proportion and clinical features of never-smokers with non-small cell lung cancer (2017) (37)
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. (2015) (37)
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. (2011) (37)
3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies (2015) (37)
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. (2006) (36)
Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. (2011) (35)
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer (2015) (35)
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases. (2015) (35)
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (2017) (35)
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib (2018) (35)
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin (2009) (35)
Clinical dissection of multicentric Castleman disease (2011) (35)
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma (2017) (34)
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation (2016) (34)
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. (2019) (34)
Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. (2009) (33)
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. (2019) (33)
Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study (2016) (32)
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus l-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL) (2014) (32)
Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis. (2012) (32)
Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. (2019) (32)
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis (2016) (32)
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. (2015) (32)
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial (2011) (31)
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression (2019) (31)
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor. (2020) (31)
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma (2020) (31)
Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial (2016) (31)
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. (2020) (31)
Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer (2018) (31)
Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (30)
Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). (2015) (30)
Metastasis-Associated Protein S100A4 and p53 Predict Relapse in Curatively Resected Stage III and IV (M0) Gastric Cancer (2008) (30)
Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung) (2012) (30)
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. (2006) (30)
MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. (2017) (28)
A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo. (2015) (28)
Optimal timing of influenza vaccination during 3‐week cytotoxic chemotherapy cycles (2017) (28)
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. (2009) (28)
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. (2004) (27)
Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). (2016) (27)
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy (2012) (27)
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. (2005) (27)
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer (2018) (27)
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines (2020) (27)
Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy (2009) (26)
Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). (2010) (26)
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer (2016) (26)
Phase II clinical trial of SKI‐2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma (1999) (26)
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma (2016) (26)
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers (2012) (26)
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma (2016) (26)
VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma (2015) (25)
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). (2013) (25)
Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis. (2014) (25)
An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicty and Enhanced Therapeutic Efficacy without Oncogenicity (2010) (25)
Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. (2010) (25)
EGFR mutations as a predictive marker of cytotoxic chemotherapy. (2012) (24)
OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab (2017) (24)
An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC. (2020) (24)
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment (2021) (24)
OA05.01 Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028 (2017) (24)
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations (2016) (24)
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial (2019) (24)
Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions. (2021) (24)
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. (2017) (23)
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors (2017) (23)
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations (2015) (23)
BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL (2014) (23)
Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1 (2015) (23)
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation (2015) (23)
Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors (2012) (23)
Influence of chemotherapy on nitric oxide synthase, indole‐amine‐2,3‐dioxygenase and CD124 expression in granulocytes and monocytes of non‐small cell lung cancer (2012) (22)
Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer (2007) (22)
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer (2017) (22)
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC (2017) (22)
Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. (2019) (22)
Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer (2005) (22)
Apoptosis inhibitor 5 increases metastasis via Erk-mediated MMP expression (2015) (21)
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement (2009) (21)
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (2014) (21)
Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. (2008) (21)
Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors (2014) (21)
Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. (2012) (21)
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and &bgr;III-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival (2009) (21)
Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). (2015) (20)
A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. (2016) (20)
Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations (2019) (20)
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. (2017) (20)
Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. (2012) (20)
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. (2019) (20)
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. (2015) (20)
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial (2014) (19)
Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. (2021) (19)
Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP. (2013) (19)
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. (2018) (19)
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer (2017) (19)
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score. (2014) (19)
Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients (2012) (19)
Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data (2012) (19)
Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. (2016) (19)
Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection (2018) (19)
Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. (2019) (19)
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer (2018) (18)
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. (2016) (18)
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients (2015) (18)
Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer. (2019) (18)
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 (2021) (18)
A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). (2018) (18)
Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells (2015) (18)
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. (2017) (18)
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. (2016) (17)
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. (2016) (17)
Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors (2015) (17)
Superior Treatment Response and In‐field Tumor Control in Epidermal Growth Factor Receptor‐mutant Genotype of Stage III Nonsquamous Non–Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy (2017) (17)
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. (2020) (17)
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. (2018) (17)
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. (2020) (17)
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status. (2018) (17)
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer (2014) (16)
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. (2015) (16)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (2019) (16)
Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer (2019) (16)
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). (2021) (16)
Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. (2017) (16)
Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007. (2016) (16)
ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC). (2017) (16)
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC). (2021) (16)
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC. (2016) (15)
Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma (2016) (15)
OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC (2017) (15)
A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors (2021) (15)
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. (2005) (15)
Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. (2017) (14)
Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. (2005) (14)
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. (2016) (14)
The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer (2017) (14)
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. (2017) (14)
A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. (2014) (14)
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). (2016) (14)
Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib (2012) (13)
Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer. (2009) (13)
Clinical Usefulness of AJCC Response Criteria for Neoadjuvant Chemotherapy in Breast Cancer (2013) (13)
Colorectal Cancer in Korea: Characteristics and Trends (2002) (13)
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. (2019) (13)
Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC). (2017) (13)
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). (2016) (13)
High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde (2011) (13)
Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC). (2018) (13)
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis (2014) (13)
P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical (2017) (12)
Significance of 18F‐FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non–small‐cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy (2019) (12)
MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC: Topic: Medical Oncology (2016) (12)
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity. (2020) (12)
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC: Topic: EGFR Biomarkers (2017) (12)
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (2016) (12)
Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate (2017) (12)
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. (2019) (11)
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment? (2018) (11)
Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial. (2014) (11)
Clinical Characteristics and Treatment Outcomes (1999) (11)
Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer (2013) (11)
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells. (2007) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. (2016) (11)
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution (2013) (11)
Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome (2006) (10)
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era (2015) (10)
Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data. (2016) (10)
Long-term disease-free survival of patients with primary cardiac lymphoma treated with systemic chemotherapy and radiotherapy (2010) (10)
Amurensin G enhances the susceptibility to tumor necrosis factor‐related apoptosis‐inducing ligand‐mediated cytotoxicity of cancer stem‐like cells of HCT‐15 cells (2013) (10)
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure (2015) (10)
Virtual reality‐assisted localization and three‐dimensional printing‐enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer (2018) (10)
Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience (2016) (10)
Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. (2021) (10)
OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials (2017) (10)
EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. (2011) (10)
A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with α fetoprotein as a predictive and prognostic marker. (2008) (9)
Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFRT790M-mutant non-small cell lung cancer. (2021) (9)
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07 (2020) (9)
Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC. (2017) (9)
A multivariate analysis of prognostic factors in colorectal cancer (2003) (9)
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC) (2015) (9)
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC (2020) (9)
Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis (2020) (9)
A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer. (2018) (9)
Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies (2019) (9)
PALETTE : Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients (2012) (9)
Clinical significance of tumor‐infiltrating FOXP3+ T cells in patients with ocular adnexal mucosa‐associated lymphoid tissue lymphoma (2011) (9)
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. (2022) (8)
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX Study. (2020) (8)
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients (2021) (8)
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP (2017) (8)
Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: Preliminary report (2013) (8)
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel (2017) (8)
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma (2021) (8)
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer (2015) (8)
9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC) (2011) (8)
A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors. (2020) (8)
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma (2014) (8)
Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type (2017) (8)
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. (2016) (8)
Long‐term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer (2008) (8)
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. (2016) (8)
The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. (2012) (7)
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors (2022) (7)
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy (2014) (7)
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study. (2020) (7)
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea (2020) (7)
Abstract PR07: AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study (2015) (7)
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous (2017) (7)
Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 (2022) (7)
Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11) (2021) (7)
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). (2017) (7)
A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer (2020) (7)
Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity (2016) (7)
Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy. (2013) (7)
The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: a retrospective cohort study. (2014) (6)
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. (2020) (6)
3030 POSTER Preliminary Characterization of Visual Events Reported by Patients (Pts) Receiving Crizotinib for the Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (2011) (6)
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma (2016) (6)
Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer. (2008) (6)
Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC. (2018) (6)
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial. (2017) (6)
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) (2021) (6)
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. (2014) (6)
Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer (2012) (6)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). (2018) (6)
MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK‐inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology (2016) (6)
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. (2022) (6)
A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. (2012) (6)
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial. (2017) (5)
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis (2019) (5)
Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. (2015) (5)
Risk stratification of symptomatic brain metastases by clinical and FDG PET parameters for selective use of prophylactic cranial irradiation in patients with extensive disease of small cell lung cancer. (2020) (5)
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. (2010) (5)
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer. (2005) (5)
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies (2019) (5)
A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). (2012) (5)
P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC (2018) (5)
Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study (2021) (5)
Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study (2021) (5)
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer (2019) (5)
P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK (2017) (5)
YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results. (2018) (4)
VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib (2011) (4)
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. (2022) (4)
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer (2018) (4)
Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. (2022) (4)
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. (2021) (4)
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies (2019) (4)
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC (2022) (4)
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors (2013) (4)
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues (2021) (4)
Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial. (2019) (4)
Nazartinib (EGF816) in patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. (2020) (4)
Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. (2011) (4)
Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (2022) (4)
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. (2022) (4)
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. (2019) (4)
The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy (2018) (3)
Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC). (2013) (3)
BMET-18ASSESSING CENTRAL NERVOUS SYSTEM (CNS) RESPONSE TO ALECTINIB IN TWO PHASE II STUDIES OF PRE-TREATED ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): RECIST VERSUS RANO CRITERIA (2015) (3)
Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study. (2020) (3)
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment (2021) (3)
MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC (2017) (3)
Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC) (2022) (3)
The CD56bright CD62L+ NKG2A+ immature cell subset is dominantly expanded in human cytokine-induced memory-like NK cells (2018) (3)
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas (2021) (3)
PS-1FIRST-LINE CRIZOTINIB VS PEMETREXED + CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK+ NSCLC IN PROFILE 1014 (2014) (3)
Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety. (2021) (3)
Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). (2016) (3)
Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study. (2022) (3)
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients. (2004) (3)
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer (2014) (3)
Preradiation Chemotherapy with ACNU-CDDP in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis (2009) (3)
Role of Radiotherapy for Squamous Cell Carcinoma of the External Auditory Canal and Middle Ear (2009) (3)
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy (2020) (3)
Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer (2021) (2)
Abstract 2416: Activity of sunitinib for lung adenocarcinoma with RET rearrangement (2015) (2)
Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies. (2016) (2)
Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial (2017) (2)
Overcoming the impact of the COVID‐19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium (2021) (2)
Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC). (2012) (2)
Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis (2017) (2)
PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors (2021) (2)
P3-140: Erlotinib treatment after progression on gefitinib in non-small cell lung cancer(NSCLC) (2007) (2)
Angioimmunoblastic T-cell Lymphoma: Clinical Characteristics and Treatment Outcomes (2005) (2)
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. (2022) (2)
Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders. (2017) (2)
Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials. (2021) (2)
Abstract 4254: Changes in PD-L1 expression during cisplatin containing treatment in patients with head and neck squamous cell carcinoma, and their association with epithelial-mesenchymal transformation (2015) (2)
Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types (2022) (2)
Phase I/II Trial (2020) (2)
A newly developed capture-based sequencing panel for genomic assay of lung cancer (2020) (2)
Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial (2020) (2)
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report. (2023) (2)
Trend of Prevalence of Pulmonary Tuberculosis Among Seoul National University Freshmen (1998) (2)
Poster Abstracts: BSTB: Prognostic Factors: BSTB: Prognostic Factors Posters, Tue, Sept 4P2-079: ERCC1 Expression by Immunohistochemistry and EGFR Mutations in Resected Non-Small Cell Lung Cancer (2007) (2)
Abstract CT193: Tepotinib + gefitinib vs chemotherapy inMET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study (2019) (2)
Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors. (2021) (2)
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. (2022) (1)
Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) (2015) (1)
Role of Postoperative Radiotherapy for Patients with Pathological Stage III Non-Small-Cell Lung Cancer after Curative Resection (2011) (1)
OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 (2017) (1)
3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC (2015) (1)
P3.02c-061 Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer: Topic: IT Biomarkers (2017) (1)
Abstract 4029: MEK pathway inhibition upregulates PD-L1 and MHC class I expression levels in head and neck squamous cell carcinoma (2016) (1)
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study. (2019) (1)
Changes Associated with Acquired Resistance to Crizotinib in ROS 1-Rearranged Non – Small Cell Lung Cancer (2015) (1)
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer (2020) (1)
Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT (2022) (1)
Title Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas : a prospective randomized controlled multicenter phase III trial (2011) (1)
Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L (2019) (1)
Quercetin Sensitizes Human Leukemic Cells to TRAIL-induced Apoptosis: Involvement of DNA-PK/Akt Signal Transduction Pathway (2009) (1)
Treatment and Prognosis for an Esthesioneuroblastoma over a 20-Year Period: Impact of Treatment Era (2009) (1)
Korean Cancer Patients’ Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate. (2016) (1)
PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR‐Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC: Topic: Medical Oncology (2016) (1)
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. (2022) (1)
Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3. (2016) (1)
BMET-35CERITINIB IN ALK+ NSCLC METASTATIC TO BRAIN AND/OR LEPTOMENINGES: THE ASCEND-7 STUDY (2015) (1)
Intracranial Relapse of Intravascular Large B-Cell Lymphoma After Completion of CHOP Chemotherapy (2004) (1)
Predict Relapse in Curatively Resected Stage III and IV ( M 0 ) Gastric Cancer (2008) (1)
Corrigendum to “Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP” [Int. J. Biochem. Cell Biol. 45 (2013) 711–723] (2013) (1)
Abstract 3157: Osimertinib (AZD9291) is effective against NSCLC cells harboringEGFRexon 20 insertion mutations (2017) (1)
Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) (2017) (1)
Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) (2016) (1)
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI). (2020) (1)
An Analysis of Treatment Results of Lymphoblastic Lymphoma in Adults According to the Chemotherapy Regimens (2003) (1)
Isolation of Monocytes with High Purity and Yield from Peripheral Blood Mononuclear Cells by Flotation Density Gradient Centrifugation (2009) (1)
Brigatinib Activity in Patients with ALK plus NSCLC and Intracranial CNS Metastases in Two Clinical Trials (2017) (1)
Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. (2014) (1)
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance (2022) (1)
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials (2022) (1)
A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment (2012) (1)
Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study. (2019) (1)
P2.12-09 Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (2019) (1)
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. (2022) (1)
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC (2022) (1)
Presence of the Raf-1 Responsive Element in Human MDR1 Promoter (1994) (1)
A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group. (2013) (1)
Abstract 3990: Clinicopathologic findings and in vitro efficacy of MYC-targeting agentsin NUT midline carcinoma (2018) (1)
Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (2012) (1)
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer (2022) (1)
The Role of Air-Vacuum Cushion Device in Patients with Rectal Cancer in Radiation Therapy. (2001) (0)
Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC). (2022) (0)
A newly developed capture-based sequencing panel for genomic assay of lung cancer (2020) (0)
Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC) (2015) (0)
Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A) (2023) (0)
Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis (2022) (0)
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis (2016) (0)
6136 POSTER Relatively High Discordant Rate of KRas Mutation Between Primary and Metastatic Sites, and a Different Pattern of KRas Mutational Status According to Metastatic Sites in Korean Patients With Colorectal Cancer (2011) (0)
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. (2023) (0)
A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ) (2012) (0)
PO-1363: Dosimetric impact of leaf open time and other planning parameters on DQA in helical tomotherapy (2020) (0)
Abstract 4553: Multiplexed, digital gene expression and fusion transcript analysis to screen forEML4-ALKpositive lung cancer (2012) (0)
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L. (2022) (0)
Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution. (2014) (0)
Effect of poly ( A ) Addition Signal on the Expression of Hepatitis B viral Sulface Antigen by EF - 1α Promoter (1993) (0)
The Effect of Cancer Associated Fibroblasts(CAFs) and CD44 of CAFs on the Motility of Cancer Cells in Head and Neck Squamous Cell Carcinoma (2014) (0)
Abstract 3500: Histone deacetylator (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA) sensitizes squamous carcinoma cells of lung to pemetrexed (2011) (0)
Abstract 3918: Kinase domain duplications of FGFR1 and MET are potential therapeutic targets (2023) (0)
Impaired NK Cytotoxicity in Cancer Patients Down-Modulation of NKG 2 D Underlies 1 Secretion and β Elevated TGF-Seog (2004) (0)
Inhibition of SIRT1 Sensitizes TRAIL-Resistant MCF-7 Cells by Upregulation of DR5 and Inhibition of c-FLIP (2012) (0)
BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study (2022) (0)
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. (2023) (0)
Ef ﬁ cacy of Brigatinib in Patients With Advanced ALK -Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) (2022) (0)
P17.17 Long term results of stereotactic radiosurgery in recurrent oligodendrogliomas (2017) (0)
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer (2021) (0)
Kaposi's varicelliform eruption after chemotherapy (2020) (0)
The efficacy of the ALK inhibitor crizotinib as compared with standard chemo- therapy as first-line treatment for advanced ALK-positive non–small-cell lung can- (2019) (0)
Monalizumab e�cacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines (2022) (0)
Abstract 5522: Anticancer activity of novel PI3K inhibitor BYL719 in head and neck cancer cell lines (2014) (0)
The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines (2022) (0)
Abstract 608: Identification of genomic alteration which affects resistance to induction chemotherapy in patients with locally-advanced head and neck squamous cell carcinoma (2015) (0)
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis (2022) (0)
MIS2. lung cancer clinical (2012) (0)
The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer. (2013) (0)
Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib (2012) (0)
Brigatinib vs crizotinib in ALK TKI-naive ALK+ NSCLC: final results from ALTA-1L (2022) (0)
A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus (2005) (0)
Abstract 1079: Prognostic role of tumor microenvironment in correlation with CD8+T cells in TCGA pan-cancer (2019) (0)
Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma. (2013) (0)
Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study (2016) (0)
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (2017) (0)
Results of Hrqol Data from Palette: A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Metastatic Soft Tissue Sarcoma (STS) Patients. An Eortc Stbsg Global Network Study (EORTC 62072) (2012) (0)
Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC (2022) (0)
A Phase II study of IMEP for Prevously Untreated Stage I/II Extranodal NK/T Cell Lymphoma , Nasal Type: Interim Analysis of KCSG-LY04-03 Trial (초) (2008) (0)
Antitumor Activity of Tepotinib plus Gefitinib in Asian Patients with Met plus EGFRm plus NSCLC (2015) (0)
Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC). (2015) (0)
AOS10 Prognostic factors for patients with leptomeningeal metastases from solid tumours (2012) (0)
Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer. (2013) (0)
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer (2020) (0)
3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC) (2015) (0)
4020 POSTER Efficacy and Toxicity of Adjuvant FOLFOX Chemotherapy in Elderly Patients With Stage III Colon Cancer – Single Center Study (2011) (0)
A case of blastic natural killer cell lymphoma presented as disseminated cutaneous lesions (2004) (0)
P3.04-024 Long-Term Outcome of Sublobar Resection versus Lobectomy for Stage I and II Non-Small Cell Lung Cancer: Topic: Miscellaneous I (2017) (0)
Quercetin Potentiates TRAIL-induced Apoptosis in Human Colon KM12 Cells (2009) (0)
Hereditary nonpolyposis colorectal cancer in endometrial cancer patients (International Journal of Cancer (2008) 122, (1077-1081)) (2009) (0)
Abstract 4946: Investigating candidate genomic alteration which affects the local recurrence in patients with desmoid fibromatosis (2015) (0)
P2-267: The efficacy and characteristics of palliative chemotherapy for elderly patients with advanced or recurrent non–small cell lung cancer (2007) (0)
Pneumocystis Pneumonia Developing during Treatment of Recurrent Renal Cell Cancer with Nivolumab (2018) (0)
Erratum (2022) (0)
WITHDRAWN:Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. (2016) (0)
BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3 (2016) (0)
The prevalence and risk factors of pneumonia after cytotoxic chemotherapy in advanced lung cancer patients: P1-256 (2007) (0)
P3.02a-016 Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC) (2017) (0)
Abstract 1498: Methylation landscape of cancers associated with immunogenicity (2019) (0)
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. (2022) (0)
OC-018: Comparison of 4 EBRTs and low-dose-rate brachytherapy for localised prostate cancer (2019) (0)
Abstract 3272: Differential sensitivities to heat shock protein 90(HSP90) inhibitors in anaplastic lymphoma kinase(ALK)-positive non-small cell ling cancer(NSCLC) cells. (2013) (0)
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. (2021) (0)
Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment? (2016) (0)
Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP) Plus L-Asparaginase As a First-Line Therapy Improves Outcomes In Stage III/IV NK/T-Cell Lymphoma, Nasal Type (NTCL) (2013) (0)
Kaplan-Meier analyses of (A) relapse free and (B) overall survival according to triple negative and (2011) (0)
Factors Associatd with Surrogate Decision-Making in Advanced Cancer Patients:a Longitudinal Study (2012) (0)
Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience. (2014) (0)
P-885 Accuracy and its affecting factors of prediction of functional reserves after lung cancer surgery (2005) (0)
High Dose Chemotherapy Using CD34+ Hematopoietic Stem Cells (1998) (0)
P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer (2014) (0)
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial (2015) (0)
P3.02a-018 Efficacy of Pemetrexed Based Chemotherapy Compared with Non-Pemetrexed Based Chemotherapy in Advanced, ALK-Positive NSCLC (2017) (0)
Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status. (2016) (0)
O pen-label, Random ized C om parison of the E fficacy of Intra- venous Dolasetron M esy late and O ndansetron in the Prevention of A cute and Delayed C isplatin-induced Em esis in C ancer Patients (2010) (0)
P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis (2017) (0)
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors (2019) (0)
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer (2023) (0)
Abstract 4461: Poor predictive power of BIM deletion polymorphism for EGFR tyrosine kinase inhibitor outcome in non-small cell lung cancer patients harboring EGFR mutation. (2013) (0)
Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. (2023) (0)
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with stage III/IV NK/T-cell lymphoma, nasal type (NTCL) (2019) (0)
Imatinib mesylate in KIT-positive advanced solid tumors excluding gastrointestinal stromal tumor (2003) (0)
Updated results from the phase 3 ALTA-1L trial of brigatinib (BRG) vs. crizotinib (CRZ) in ALK inhibitor-naive advanced ALK plus NSCLC (2020) (0)
Abstract 1842: Synergistic inhibition of ALK inhibitor-resistant lung cancer cells by dual-targetingEGFRandALKpathways (2014) (0)
Abstract 652: PD-L1 and MHC class 1 expression levels are modulated by MEK inhibition on head and neck squamous cell carcinoma (2017) (0)
Abstract B27: Osimertinib (AZD9291) is sensitive and bound with affinity to EGFR exon 20 insertion mutant models (2018) (0)
TGF-β1 induces dysfunction of NK and T cells through non-apoptotic NKG2D modulation in cancer patients (2005) (0)
Abstract 2181: Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) (2023) (0)
Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea. (2017) (0)
Abstract 3032: Acquired resistance to osimertinib in patients withde novo EGFRT790M-positive non-small cell lung cancer (NSCLC) (2019) (0)
Kaplan-Meier analyses of survival according to clinical and pathologic stages (2011) (0)
Abstract 5201: Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: Therapeutic implications for immune checkpoint inhibitors (2018) (0)
9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE) (2011) (0)
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in Anaplastic lymphoma kinase-rearranged lung cancer (2008) (0)
Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis (2022) (0)
A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas (2020) (0)
Anti-cancer activity of gemcitabine against chemo-resistant natural killer (NK) cell leukemia-lymphoma (2008) (0)
ALK Molecular Phenotype in n on- s mall cell lung cancer: (2014) (0)
P2-231: Palliative Chemotherapy for Pulmonary Pleomorphic Carcinoma (2007) (0)
O3-4-1Phase II study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC) (2017) (0)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non – Small Cell Lung Cancer HarboringWild-Type Epidermal Growth Factor Receptor AMeta-analysis (2014) (0)
A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017) (2017) (0)
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. (2022) (0)
Detecting ALK fusions in lung cancer: multiple choice testing? (2013) (0)
P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70: Topic: Clinical Trials (2017) (0)
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who (2021) (0)
Hepatitis C Virus Core Protein Sensitizes Cells to Apoptosis Induced by Anti-Cancer Drug (1999) (0)
Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (2012) (0)
BMET-37PHASE I STUDY OF AZD3759, AN EGFR INHIBITOR WITH BLOOD BRAIN BARRIER (BBB) PENETRATION, FOR THE TREATMENT OF EGFRm+ NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASIS AND LEPTOMENGINGEAL METASTASIS (2015) (0)
' s response to reviews Title : Prognostic impact of clinicopathologic parameters in stage II / III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy : paradoxical features of the triple negative breast cancer (2007) (0)
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (0)

This paper list is powered by the following services:

Dong‐wan Kim's Academic­Influence.com Rankings

Dong‐wan Kim's Degrees

Why Is Dong‐wan Kim Influential?

Dong‐wan Kim's Published Works

Published Works

Dong‐wan Kim's AcademicInfluence.com Rankings